Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients

Keyphrases

• Granulocyte Colony-stimulating Factor (G-CSF) 100%
• Cyclophosphamide 100%
• Doxorubicin 100%
• Time to Progression 100%
• Metastatic Breast Cancer 100%
• Doxorubicin-cyclophosphamide 100%
• Intensive Chemotherapy 100%
• Dose-intensive 100%
• Left Ventricular Ejection Fraction 33%
• Neutropenia 33%
• Dose-response Relationship 33%
• Breast Cancer Patients 33%
• Palliative Treatment 33%
• Complete Response 33%
• Median Survival 33%
• Median Time 33%
• Thrombocytopenia 33%
• Mucositis 33%
• Antitumor Activity 33%
• 6-cycles 33%
• Complete Remission 33%
• Escalating Dose 33%
• Number of Cycles 33%
• Dose Finding 33%
• Advanced Breast Cancer 33%
• Dose Reduction 33%
• Cumulative Toxicity 33%
• High Response Rate 33%
• Acute Toxicity 33%
• Dose-dense Chemotherapy 33%
• Therapy Discontinuation 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemotherapy 100%
• Doxorubicin 100%
• Cyclophosphamide 100%
• Granulocyte Macrophage Colony Stimulating Factor 100%
• Metastatic Breast Cancer 100%
• Breast Cancer 25%
• Side Effect 25%
• Dose-Response Relationship 25%
• Remission 25%
• Thrombocytopenia 25%
• Neutropenia 25%
• Mucosa Inflammation 25%
• Weakness 25%
• Antitumor Activity 25%